Durvalumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD274 |
| Identifiers | |
| CAS Number | 1428935-60-7 |
| ATC code | none |
| IUPHAR/BPS | 7985 |
| ChemSpider | none |
| Chemical data | |
| Formula | C6502H10018N1742O2024S42 |
| Molar mass | 146.3 kg/mol |
Durvalumab[1] is a monoclonal antibody being investigated for the treatment of cancer.[2] It targets programmed death ligand-1 (PD-L1).[3]
This drug was developed by MedImmune.
Clinical trials
A phase 1B clinical trial of durvalumab and tremelimumab showed some activity in non-small cell lung cancer (NSCLC).[3] Phase 1 data in advanced metastatic urothelial bladder (Study 1108) has led to FDA breakthrough therapy designation.[4]
References
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information 28 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Durvalumab, American Medical Association.
- 1 2 Astrazeneca’s combination of durvalumab with tremelimumab shows clinical activity in non-small cell lung cancer irrespective of PD-L1 status. Feb 2016
- ↑ AstraZeneca's (AZN) Durvalumab Granted FDA Breakthrough Therapy Designation. StreeInsider.com Corporate News, FDA, Management Comments. February 17, 2016.
This article is issued from Wikipedia - version of the Sunday, March 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.